PipelineReview.com1d
Amgen and Kyowa Kirin provide top-line results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis
About the ROCKET Phase 3 Program ROCKET is a comprehensive, global Phase 3 clinical trial program comprised of eight studies intended to establish the safety and efficacy profile of rocatinlimab in ...
PipelineReview.com1d
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
PARIS, France and TARRYTOWN, NY, USA I March 8, 2025 I Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent ...
PipelineReview.com1d
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm ...
PipelineReview.com1d
Innovation fuels the biologics market growth of therapeutic antibodies and proteins in 2024
The report covers 2024 sales data of innovator therapeutic antibodies and proteins, biosimilars and the novel biologic drug modalities gene & cell therapy ...
PipelineReview.com2d
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
BRIDGEWATER, NJ, USA and BENGALURU, India I March 7, 2025 I Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and ...
PipelineReview.com2d
Dual WEE1/YES1 Kinase Inhibitor MRANK-106 Secures FDA IND Clearance, Positioning MindRank in First-in-Class Oncology Pipeline
HANGZHOU, China and LONDON, UK I March 07, 2025 I MindRank, a clinical stage artificial intelligence (AI)-empowered drug discovery company, announces today ...
PipelineReview.com2d
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three ...
PipelineReview.com3d
Anova Announces First Patient Enrolled to Phase 1/2a Study of DB107 for the Treatment of High-Grade Gliomas
LONDON, UK & CHICAGO, IL, USA I March 05, 2025 I Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, ...
PipelineReview.com3d
Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine
SHANGHAI, China I March 6, 2025 I Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, ...
PipelineReview.com3d
Neurotech’s ENCELTO™ (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Macular Telangiectasia Type 2 (MacTel)
ENCELTO is the First and Only FDA-approved Treatment for MacTel. CUMBERLAND, RI, USA I March 06, 2025 I Neurotech Pharmaceuticals, Inc., a private biotech company focused on d ...
PipelineReview.com3d
CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL
SUZHOU, China I March 5, 2025 I CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer ...
PipelineReview.com3d
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
SAN DIEGO, CA, USA I March 5, 2025 I Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the ...